Science 37 Holdings, Inc. (SNCE) Tops Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Science 37 Reports Second Quarter 2022 Financial Results
August 11, 2022 6:00 AM EDTRESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (Science 37) the Agile Clinical Trial Operating System, today reported its financial results for the quarter ended June 30, 2022.
"We made meaningful strides across our strategic priorities in the second quarter and our pathway to profitability. We believe this commitment has materialized into strong revenue growth, sales pipeline expansion, and notably, margin improvement and sustainable cash burn, said David Coman, Chief Executive Officer of Science 37. We remain focused on leading the way as a pioneer in agile... More



